Medium-dose riboflavin as a prophylactic agent in children with migraine: A preliminary placebo-controlled, randomised, double-blind, cross-over trial by Bruijn, J.K.J. (Jacques) et al.
 http://cep.sagepub.com/
Cephalalgia
 http://cep.sagepub.com/content/30/12/1426
The online version of this article can be found at:
 
DOI: 10.1177/0333102410365106
 2010 30: 1426 originally published online 26 March 2010Cephalalgia
Jacques Bruijn, Hugo Duivenvoorden, Jan Passchier, Heiko Locher, Natascha Dijkstra and Willem-Frans Arts
placebo-controlled, randomised, double-blind, cross-over trial
Medium-dose riboflavin as a prophylactic agent in children with migraine: A preliminary
 
 
Published by:
 http://www.sagepublications.com
On behalf of:
 
 
 International Headache Society
 can be found at:CephalalgiaAdditional services and information for 
 
 
 
 
 
 http://cep.sagepub.com/cgi/alertsEmail Alerts: 
 
 http://cep.sagepub.com/subscriptionsSubscriptions:  
 http://www.sagepub.com/journalsReprints.navReprints: 
 
 http://www.sagepub.com/journalsPermissions.navPermissions: 
 
 at Erasmus Univ Rotterdam on August 25, 2011cep.sagepub.comDownloaded from 
Original Article
Medium-dose riboflavin as a prophylactic
agent in children with migraine:
A preliminary placebo-controlled,
randomised, double-blind, cross-over trial
Jacques Bruijn1,2, Hugo Duivenvoorden3, Jan Passchier3,4,
Heiko Locher2, Natascha Dijkstra2 and Willem-Frans Arts2
Abstract
Background: Riboflavin seems to have a promising effect on migraine in adults. The present study examines whether
riboflavin has a prophylactic effect on migraine in children.
Objective: To investigate whether riboflavin in a dosage of 50mg/day has a prophylactic effect on migraine attacks in young
children.
Subjects and methods: This randomised, placebo-controlled, double-blind, cross-over trial included 42 children (aged 6–13
years) with migraine of whom 14 children were also suffering from tension-type headache. Following a 4-week baseline
period, all children received placebo for 16 weeks then riboflavin for 16 weeks (or vice versa) with a washout period of
4 weeks in between. The primary outcome measure was reduction in mean frequency of migraine attacks and
tension-type headache in the last 4 weeks at the end of the riboflavin and placebo phase, compared with the preceding
baseline or wash-out period. Secondary outcome measures were mean severity and mean duration of migraine and
tension-type headaches in the last 4 weeks at the end of the riboflavin and placebo phase, compared with the preceding
baseline or wash-out period.
Results: No significant difference in the reduction of mean frequency of migraine attacks in the last month of treatment
was found between placebo and riboflavin (P¼ 0.44). However, a significant difference in reduction of mean frequency of
headaches with a tension-type phenotype was found in favour of the riboflavin treatment (P¼ 0.04).
Conclusions: In this group of children with migraine, there is no evidence that 50mg riboflavin has a prophylactic effect on
migraine attacks. We found some evidence that 50mg riboflavin may have a prophylactic effect on interval headaches that
may correspond to mild migraine attacks or tension-type headache attacks in children with migraine.
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Introduction
Migraine is a common disorder in adolescents and chil-
dren. The prevalence of headache and migraine is age
and gender dependent. Sillanpa¨a¨ (1) reported a preva-
lence of migraine for boys and girls at 7 years of age of
2.9% and 2.5%, respectively; at age 14 years, the prev-
alence of migraine was 6.4% and 14.8% for boys and
girls, respectively.
The efficacy of both pharmacological and
non-pharmacological interventions in children and
adolescents with migraine has been studied extensively
(2–5). Some interventions in the field of symptomatic
treatment of migraine in children have been proven
effective, such as sumatriptan nasal spray, ibuprofen
and acetaminophen (2,5). In the prophylactic treatment
of migraine in children and adolescents, until now only
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flunarizine is an evidence-based effective drug, and
probably also topiramate (4–6). Adverse effects have
been reported in both treatments. In addition, flunar-
izine is not available in the US and both flunarizine and
topiramate cannot be prescribed to children or adoles-
cents in most European countries (4–6). Other treat-
ment modalities in this field (which are not evidence
based) are antihypertensive medications, antidepres-
sants, serotonergic drugs, 5-HT2-antagonists (such as
pizotifen or methysergide) and anti-epileptic drugs.
However, in all of these agents, adverse effects have
been described (4,5). Thus, there is a need for
high-quality research to evaluate pharmacological pro-
phylactic treatment that has minimal or no adverse
effects in children and in adolescents with migraine.
From this perspective we were interested in examin-
ing riboflavin (vitamin B2). Riboflavin is a co-factor for
mitochondrial oxidative phosphorylation as it is the
precursor for the flavin compounds necessary for the
transfer of electrons in the mitochondrial respiratory
chain. In vivo studies have detected an impairment of
mitochondrial oxidative phosphorylation in adult
migraineurs between attacks (7–9). Supraphysiological
doses of riboflavin might be helpful in reducing this
impairment. In patients with mitochondrial encephalo-
pathy with lactic acidosis and stroke-like episodes, a
subgroup had a reduced frequency of migraine attacks
during treatment with riboflavin (10). Therefore, ribo-
flavin has been used as a prophylactic agent in studies
on adults with migraine, including two open-label stu-
dies (11,14) and two randomised controlled trials
(12,13). In these latter trials, riboflavin was proven
effective with minimal adverse effects. These adverse
effects were diarrhoea (1 of 43 adults with migraine
treated with riboflavin) and polyuria (1 of 43 adults
with migraine treated with riboflavin) (12,13). A
common and harmless side effect of riboflavin is a
bright yellow/orange discolouration of the urine.
At the time of the present study, no other trials were
registered to investigate the effect of riboflavin in chil-
dren with migraine. Therefore, we decided to perform a
placebo-controlled, randomised trial in children with
migraine using riboflavin as the active agent.
Subjects and methods
A 40-week, randomised, double-blind, cross-over
design was used to examine the effect of riboflavin com-
pared with placebo in young children with migraine.
The study was conducted in two hospitals in The
Netherlands. The children were prospectively recruited
between October 2005 and March 2008, and the trial
was completed in December 2008. The children were
referred by general practitioners (in the region of
Schiedam/Vlaardingen) and by paediatricians, neurolo-
gists and paediatric neurologists in the greater
Rijnmond region in The Netherlands.
All potentially referring physicians received an infor-
mation letter about this trial. The children were
assessed at the out-patient paediatric department of
Vlietland Hospital (in Schiedam/Vlaardingen) by the
principal investigator (JB), and at the department of
paediatric neurology of the Erasmus Medical Centre
(EMC, Rotterdam) by the principal investigator (JB)
and the co-investigators (ND and WFA).
Parental informed consent, and informed consent
from children aged 12 years, was obtained. Headache
diaries were composed in advance of the trial. The
study was approved by the Medical Ethics committees
of the EMC and Vlietland Hospital.
Subjects
The inclusion criteria were: (i) age 6–13 years – we
deliberately chose this age group because only a limited
number of evidence-based interventions on this group
are available (2–5); (ii) migraine with or without
aura according to the ICHD II criteria (15); and (iii)
a frequency of two or more headache attacks per
month.
The exclusion criteria were: (i) epilepsy or other seri-
ous neurological disease; (ii) diseases of the liver or
kidneys, and gastrointestinal, metabolic or cardiovas-
cular disease; (iii) use of other prophylactic medication
for migraine within 1 month of the trial; (iv) use
of other prophylactic treatment for migraine during
the trial; and (v) inability to comply with the require-
ments of the trial, and/or inability to speak and read
Dutch.
Procedure and intervention
The pharmacy department of the EMC manufactured
placebo and riboflavin capsules, the latter containing
50mg riboflavin. To ensure the double-blind design,
carotene 100mg was used as placebo. Both carotene
and riboflavin give an orange discolouration of the
urine. A PubMed search confirmed the absence of evi-
dence that carotene has any effect on headache fre-
quency or intensity in children.
After a baseline period of 4 weeks, children were ran-
domised in phase 1 to receive either one capsule contain-
ing placebo or 50mg riboflavin daily for 16 weeks.
Children were instructed to swallow the capsule at
breakfast. Following a wash-out period of 4 weeks, in
phase 2 the children received either one capsule contain-
ing placebo daily for 16 weeks if they had received ribo-
flavin in phase 1, or one capsule of 50mg riboflavin daily
for 16 weeks if they had received placebo in phase 1.
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Treatment allocation was concealed from the partici-
pants and investigators for the duration of the study.
The hospital pharmacists guarded the randomisation
key. To evaluate blinding, at the last visit parents were
asked which treatment they believed that their child had
received in which phase, and the reasons for their
assumptions.
All children were primarily diagnosed with migraine
by paediatric neurologists (JB or WFA). A thorough
history was taken, and a complete neurological and
physical examination was performed including mea-
surement of blood pressure, body weight, height and
skull circumference.
If the child was eligible for inclusion, the child and
their parents were informed about all aspects of the
trial and asked for their consent. They were informed
that they could end their participation at any time
during the trial without having to give any reason.
No rewards or other response-enhancing policies
were applied. A 2-week period was allowed for the
child/parents to consider possible participation in the
study.
The parents of the children were asked to keep a
detailed headache diary during all stages of the study.
This headache diary documented every headache
attack, including: the date, the severity of the headache
on a 4-point Likert scale, its location(s), duration and
nature (pulsating or non-pulsating), possible aggrava-
tion by routine physical activity, associated symptoms
such as nausea or vomiting, and the presence or
absence of photophobia or phonophobia or fever.
The diaries were based on the ICHD-II criteria in
order to enable classification of each headache attack
as a migraine attack, tension-type headache, headache
probably due to an (ear-nose-throat) infection, or a
headache attack not fulfilling the ICHD-II criteria of
any of these. Parents also completed questionnaires on
behavioural problems and life dimensions of the chil-
dren for a different research focus (not reported here).
All parents and children received information
regarding childhood migraine, and all children were
treated symptomatically according to state-of-the-art
evidence-based guidelines (5,16).
This meant that, in case of a migraine attack,
they received acetaminophen and ibuprofen orally or
rectally, and sumatriptan nasal spray if they were 12
years old.
Children were given simple instructions on how to
improve sleep duration and quality, i.e. to stop the
intake of caffeine, and decrease the amount of time
spent watching television or computer activity to a
maximum of 2–3 h per day.
Appointments with parents were made at the end of
each stage. At each appointment, the headache diary of
the preceding stage was given by the parents to the
paediatric neurologists (JB or WFA), and, in return, a
new headache diary for the following stage was given to
the parents. During the trial, halfway in both phase 1
and phase 2, paediatric neurologist JB or co-
investigator ND, would hold a telephone conversation
with the parents.
At each visit and each telephone appointment, the
parents were consistently asked about any possible
adverse effects of the medication. This was documented
in the personal file of the child. To improve compliance
during both phases of the study, parents and child were
asked to bring the remaining tablets with them at each
visit.
Three months after the conclusion of the trial, all
parents and children received a letter informing them
when their child had received riboflavin or placebo, and
the preliminary conclusions of the trial.
Outcome measures
The outcome measures were reduction in the mean fre-
quency, mean severity and mean duration of migraine
and tension-type headache in the last 4 weeks at the end
of phase 1 and of phase 2 compared with the baseline
and washout period, respectively. Any adverse effects
were documented and compared.
Statistical analysis
Sample size calculations were based on a clinically rel-
evant difference of 0.60 SD between the riboflavin and
placebo condition in favour of riboflavin with regard to
migraine frequency in accordance with the data of the
randomised controlled trial by Schoenen et al (12). In
addition, based on a cross-over design, an a of 0.05
(two-sided) and a statistical power of 0.80, a minimum
number of 20 patients was required to participate in the
trial. To allow for drop-outs, 30 patients were initially
enrolled, which was later extended to 42 to allow also
for exploratory analysis.
Statistical analysis was performed according to the
intention-to-treat principle. As measures of central ten-
dency, the mean values (for continuous data) and per-
centages (for categorical data) were estimated. In case
of continuous data, the SD was used as measure of
dispersion. To evaluate the effect of riboflavin on the
outcome variables, the t-test for independent observa-
tions was applied (17). All statistical testing took place
at the 0.05 level of significance.
We planned an exploratory analysis with regard to
the effect of riboflavin versus placebo on tension-type
headache. We also planned an exploratory analysis in
children with a relatively high baseline headache attack
frequency versus children with a relatively low baseline
headache attack frequency.
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Results
Demographics
A total of 57 children were assessed for eligibility; 15
patients were not enrolled because they did not meet
the inclusion criteria, met one or more exclusion crite-
ria, or because the parents or child refused to partici-
pate in the trial (Fig. 1).
Of the 42 children that were randomised, 20 were
randomised to receive riboflavin during phase 1 and
placebo during phase 2, whereas 22 children received
placebo during phase 1 and riboflavin during phase 2.
In this latter group, during the placebo phase, one child
was lost to follow-up, the parents of two children with-
drew their consent for further participation, and one
patient proved to be suffering from headache due to
medication overuse, discovered after careful study of
her baseline headache diary. Both treatment groups
had comparable demographic and migraine features
(Table 1). Of the 20 children who were randomised to
receive riboflavin in the first and placebo in the second
phase, 10 (50%) were also suffering from tension-type
headache. Of the 22 children who were randomised to
receive first placebo and riboflavin in the second phase,
four (18%) were also suffering from tension-type
headache.
Outcome data
The outcome data are summarized in Table 2A,B. No
significant difference in the reduction of the mean fre-
quency of migraine attacks in the fourth and last month
*CONSORT indicates Consolidated Standard of Reporting Trials.  
Randomised  (n=42) 
Asessed for eligibility
(n=57)
Excluded (n=15)
· not meeting inclusion criteria (n=2)
· presence of exclusion criteria (n=3)
· refused to participate (n=10)
Enrollment (n=42) 
baseline period: 4 weeks 
Allocated to riboflavin
(n=20)
phase 1: 16 weeks
Allocated to placebo
(n=22)
phase 1: 16 weeks
Allocated to riboflavin 
(n=18)
phase 2: 16 weeks 
Allocated to placebo
(n=20)
phase 2: 16 weeks   
Wash-out (n=20):
4 weeks 
Wash-out (n=18):
4 weeks
Discontinued intervention (n=4)
· refusal of further participation (n=2)
· presence of exclusion criteria (n=1)
· lost to follow-up (n=1)
Analyzed (n=18) Analyzed (n=20)
Figure 1. The Consolidated Standard of Reporting Trials (CONSORT) flow diagram showing the flow of participants.
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of treatment was found between placebo and riboflavin
(P¼ 0.44). However, we did find a significant difference
in the reduction of the mean frequency of attacks of
tension-type headache in favour of the riboflavin treat-
ment (P¼ 0.04).
No significant difference was found in change or
reduction of mean intensity of migraine attacks and
tension-type headache attacks in the fourth and last
month of treatment between placebo and riboflavin
(P¼ 0.18 and did not apply, respectively). Also, no sig-
nificant difference was found in change or reduction of
mean duration of migraine attacks and tension-type
headache attacks in the fourth and last month of treat-
ment between placebo and riboflavin (P¼ 0.15 and did
not apply, respectively).
Analysis for a period or carry-over effect was per-
formed on all outcome measures but proved to be
inconclusive.
An exploratory analysis of attack frequency in
children with a relatively high baseline frequency
of five or more attacks per month, and in children
with four or less attacks per month at baseline,
revealed no significant differences in both of these cate-
gories between riboflavin and placebo with regard to
migraine prophylaxis (P¼ 0.36 and P¼ 0.29,
respectively).
During the trial, no adverse effects were reported
by parents or children; this was recorded in the
patient files in both the riboflavin-placebo and the
placebo-riboflavin groups.
Discussion
With regard to prophylaxis of migraine attacks, there
was no significant difference in the mean migraine fre-
quency per 4 weeks (P¼ 0.44) or mean intensity of
migraine attacks (P¼ 0.18) or mean duration of
migraine attacks (P¼ 0.15) in the last 4 weeks of treat-
ment between riboflavin and placebo. It could be
argued that this result might be due to the fact that
we had no upper limit for attack frequency as an exclu-
sion criterion. In children, a high frequency of migraine
or headache attacks, especially with an attack fre-
quency of 15 headache attacks per month or more
(the main diagnostic criterion for chronic migraine/
headache), is often indicative of resistance to pharma-
cological prophylactic treatment (18). Therefore, we
also performed a separate exploratory analysis of
attack frequency in children with a relatively high base-
line frequency (five or more attacks per month), and in
children with a relatively low baseline frequency (four
or less attacks per month). In both of these categories,
no significant differences were found between riboflavin
and placebo with regard to migraine prophylaxis.
Our conclusions are in line with those of MacLennan
et al. (19), who investigated 48 children with migraine
aged 5–15 years (mean, 11.1 2.1 years) with a higher
dosage of 200mg riboflavin per day in a placebo-
controlled, double-blind, randomised trial with a
parallel group design. This latter trial also reported no
differences between riboflavin and placebo for primary
Table 1. Baseline demographic and clinical characteristics of the study group
Characteristic
Riboflavin-placebo
(n¼ 20)
Placebo-riboflavin
(n¼ 22)
Age in years (mean SD) 9.91 1.89 9.50 1.63
Male 12 (60%) 12 (54%)
Migraine with aura 9 (45%) 8 (36%)
Other headache types
Nil other than migraine 8 (40%) 15 (68%)
Tension-type headache 10 (50%) 4 (18%)
Headache by ENT infection 1 (5%) 0 (0%)
Other 3 (15%) 2 (9%)
Family history of migraine 16 (89%) 19 (95%)
Years since onset of migraine (mean SD) 3.06 1.73 2.80 2.14
Number of migraine attacks per month (mean SD) 3.60 3.10 3.48 5.41
Duration of migraine attacks in hours (mean SD) 2.45 1.19 2.57 1.54
Migraine prophylaxis used in the past 2 (10%) 4 (18%)
Use of paracetamol as symptomatic treatment 13 (65%) 17 (77%)
Use of ibuprofen as symptomatic treatment 4 (20%) 6 (27%)
Use of sumatriptan as symptomatic treatment 4 (20%) 5 (23%)
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Table 2(B). Analysis of headache frequency, intensity and duration in the last 4 weeks by riboflavin or placebo treatment
Parameter
Difference a period 1
(start-end)
Difference b period 2
(start-end) Difference a–b Testing
n Mean SD n Mean SD n Mean SD t-Statistic P-value
RP migraine frequency
(per 4 weeks)
20 1.55 4.41 20 1.65 2.16 20 0.10 4.69 0.79 0.44
RP TTH frequency
(per 4 weeks)
20 0.80 1.51 20 0.05 1.05 20 0.75 1.86 2.12 0.04*
PR migraine frequency
(per 4 weeks)
17 0.94 1.92 18 0.06 1.83 16 0.86 2.66
PR TTH frequency
(per 4 weeks)
17 0.06 0.97 18 0.39 0.98 16 0.43 1.50
RP migraine intensity
(0–3)
13 0.62 0.78 12 0.34 0.81 8 0.94 1.08 1.47 0.18
RP TTH intensity
(0–3)
3 0.70 0.69 4 0.42 0.50 3 0.15 0.80 dna dna
PR migraine intensity
(0–3)
11 0.13 0.76 8 0.15 0.64 5 0.13 0.86
PR TTH intensity
(0–3)
dna dna dna dna 0.67 dna dna dna dna
RP migraine duration 11 0.71 1.26 10 0.06 1.15 6 0.55 1.64 1.58 0.15
RP TTH duration 3 1.08 2.09 2 1.71 1.47 2 1.58 1.29 dna dna
PR migraine duration 9 0.59 1.28 8 0.06 1.09 5 0.68 0.89
PR TTH duration dna dna dna dna 1.33 dna dna dna dna
n, number of patients; TTH, tension-type headache; dna, did not apply; RP, order riboflavin-placebo; PR, order placebo-riboflavin; *significant (P< 0.05);
bold numbers, difference between start and end of riboflavin treatment; italic numbers, difference between start and end of placebo treatment;
t-statistic and P-value for difference between difference ab for order of RP and PR, respectively.
Table 2(A). Data on headache frequency, intensity and headache duration in the last 4 weeks by riboflavin or placebo treatment
Parameter
Period 1 baseline Period 1 end Period 2 wash-out Period 2 end
n Mean SD n Mean SD n Mean SD n Mean SD
RP migraine frequency
(per 4 weeks)
20 3.60 3.10 20 2.05 2.69 20 3.05 2.91 20 1.40 1.55
RP TTH frequency
(per 4 weeks)
20 1.35 1.56 20 0.55 1.82 20 0.65 0.99 20 0.60 1.05
PR migraine frequency
(per 4 weeks)
21 3.48 5.41 18 1.61 1.42 18 1.94 1.92 18 2.00 2.35
PR TTH frequency
(per 4 weeks)
21 0.24 0.54 18 0.33 0.59 18 0.56 0.98 18 0.17 0.38
RP migraine intensity
(0–3)
19 1.85 0.54 14 2.39 0.84 16 2.28 0.75 14 2.05 0.81
RP TTH intensity (0–3) 10 1.08 0.92 3 1.63 0.55 9 0.67 0.71 6 1.44 1.03
PR migraine intensity
(0–3)
20 1.94 0.80 13 1.85 0.88 12 2.27 0.78 13 2.08 0.82
PR TTH intensity (0–3) 4 1.00 0.82 5 1.00 1.00 5 1.13 1.14 3 1.33 1.15
RP migraine duration (h) 18 2.45 1.19 13 3.08 1.23 15 3.13 1.04 13 2.93 1.07
RP TTH duration (h) 9 3.00 1.36 3 2.70 1.92 10 1.50 1.38 4 3.13 0.88
PR migraine duration (h) 20 2.57 1.54 11 2.14 1.49 11 2.76 1.40 12 2.47 1.21
PR TTH duration (h) 2 0.25 0.35 4 0.87 0.62 4 2.08 1.89 3 1.50 2.32
n, number of patients; TTH, tension-type headache; RP, order riboflavin-placebo; PR, order placebo-riboflavin; bold numbers¼ after riboflavin
treatment; italic numbers¼ after placebo treatment.
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or secondary outcome variables with regard to migraine
prophylaxis. The trial of MacLennan et al. had an upper
limit exclusion criterion of eight migraine attacks per
month. They recommended performing future studies
with a cross-over design, or with larger sample sizes.
The fact that both our crossover study and that of
MacLennan et al. showed no proof of effectiveness of
riboflavin as a prophylactic agent in children with
migraine is in contrast to the riboflavin studies con-
ducted among adults with migraine (11–14).
The strength of our study is the double-blind, ran-
domised, placebo-controlled, cross-over design, which
gives more statistical power than a parallel design. Of
the four drop-outs during the study, all were in the
placebo-riboflavin group and dropped out during the
placebo phase. It can be argued that this might be due
to the lower effect of placebo compared with riboflavin.
However, analysis of the other children in the
riboflavin-placebo group showed a slightly better
(non-significant) response to the placebo phase com-
pared with the riboflavin phase.
A weakness of our study, on the other hand, could be
the 50mg per day dosage of riboflavin. Riboflavin has
beenused as a therapeutic agent in variousmitochondrial
diseases in children and adolescents, such as theNADH–
CoQ reductase deficient myopathy and the mitochon-
drial encephalopathy and stroke studies (10,20). In
these latter studies, riboflavin was given in doses appro-
ximately 100-fold higher than the normal dietary intake,
e.g. between 100 and 300mg per day. These dosages were
well tolerated without adverse effects (except for nausea)
and sometimes yielded striking improvement (20).
Before the start of our study, three trials in adults
with migraine (all using 400mg riboflavin per day) had
suggested a dosage of 100–200mg per day for children
(12–14). However, shortly before the start of our trial,
Maizels et al. (21) demonstrated no significant difference
between a combination of high-dose riboflavin, magne-
sium and feverfew in comparison with a low dose
(25mg) of riboflavin acting as placebo in adults with
migraine, suggesting an equivalent effect of low-dose
riboflavin versus high-dose riboflavin. Therefore, we
decided to treat our 6–13-year-old patients with a
dosage of 50mg riboflavin, which is relatively low com-
pared with the dosage used in mitochondrial diseases
and in riboflavin studies in adults with migraine.
On the other hand, if one assumes that children have
a much higher metabolic rate than adults, the maxi-
mum dosage of riboflavin in children should be even
higher than in adults to obtain a similar effect. From
this perspective, our attention was drawn to the recent
publication of Condo` et al. (24), which describes a ret-
rospective open-label study in 41 children or adoles-
cents with migraine who were treated with 200mg or
400mg riboflavin on a daily basis for 3–6 months.
In that study, 68.4% of the included children had a
reduction of 50% or more in the frequency of all head-
ache attacks. Statistical analysis showed no significant
differences between frequency/intensity responders for
a 200mg or 400mg/day dose. However, in that study,
no placebo group was included and treatment was not
concealed, which are essential factors for assessing
study quality.
Another point for discussion could be the dura-
tion of 16 weeks of each treatment period, and
the analysis that was limited to the last 4 weeks of both
phases of the study. This set-upwas based on the original
riboflavin trial of Schoenen et al. (12) among adults with
migraine. In that study, the maximal effect of riboflavin
was seen in the fourth month of treatment (12).
In addition, the relatively small number of partici-
pants might be a factor explaining the negative results
of our trial. However, our power estimation was accord-
ing to standard criteria. Future studies using a rando-
mised, controlled, parallel group design according to
IHS guidelines, should employ a larger sample size.
One can also argue that, based on the low percentage
of children receiving migraine prophylaxis in both the
riboflavin-placebo and the placebo-riboflavin group
(10% and 18%, respectively), the effectiveness of ribo-
flavinwas less significant due to the limited severity of the
headache symptoms in the included children. However,
in our opinion, these low percentages of migraine pro-
phylaxis at inclusion do not mean that the severity of
symptoms was less significant. First, the included chil-
dren were relatively young (6–13 years) andmigraine has
a relatively low prevalence in pre-pubertal children com-
pared with adolescents and adults. Therefore, most chil-
dren in our study had a relatively short history of
migraine. Second, most children were included after
their first consultation with a specialist to whom they
were referred by the general practitioner (GP) because
of their headache; in the Dutch healthcare system, the
GP is the key person for referral to a specialist. Referral
to, or consultation with, a specialist is advised in the
national Dutch guidelines for GPs if there is a need for
prescribing symptomatic or prophylactic treatment in
children with migraine. Finally, an earlier study from
our group showed that the quality of life is very poor
in children with migraine and tension-type headache at
their first visit to one of the two hospitals whichwere also
used for inclusion and follow-up procedures in the pre-
sent study (25); this suggests that GPs in The
Netherlands tend to refer only children with a high
burden of headache or migraine. It is for these reasons
that most of the children in the present study did not
receive prophylactic treatment, and not because of lim-
ited severity of their headache symptoms.
A final drawback is that, in all trials among children
with migraine (both for acute treatment and migraine
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prophylaxis), a high placebo response made it difficult to
prove the efficacy of a verum drug (22). This will also
apply to our study, especially since all children were
given simple instructions about improving sleep quality
and duration, stopping intake of caffeine, and decreasing
the amount of time spent watching television or using a
computer (besides receiving state-of-the-art, evidence-
based, symptomatic treatment), which undoubtedly
increased the placebo response in all the included
children.
In addition, an interesting hypothesis that might
explain our negative findings is related to the mitochon-
drial DNA make-up of our patients.
A recent pharmacogenetic study in adults with
migraine showed that patients with non-H mitochon-
drial DNA haplotype respond better to treatment with
riboflavin than patients with H-mitochondrial DNA
haplotype (23). To investigate if this is a significant
factor, mitochondrial DNA analysis should be per-
formed and the presence of non-H or H-haplotype
mitochondrial DNA should be taken into account in
the analysis of our data.
In summary, with regard to effectiveness, based on
our present study and those of Condo` et al. (24) and
MacLennan et al. (19), we conclude that, at this
moment, there is inconclusive evidence for the effective-
ness of riboflavin on migraine attacks in children or
adolescents with migraine.
With regard to safety, in our present study none of
the included children experienced adverse effects. In the
study of Condo` et al. (24), two patients experienced
vomiting and increased appetite, respectively, during
riboflavin treatment. This was most likely unrelated
to the use of riboflavin. In the study of MacLennan
et al. (19), none of the children on riboflavin experi-
enced adverse effects. Therefore, one can now conclude
that riboflavin in dosages up to 400mg daily for a
period of several months can be safely used in children
with migraine.
Finally, we found some evidence that riboflavin may
have a prophylactic effect on tension-type headache in
children with migraine.
Unfortunately, due to the low numbers of patients
involved, calculation of significant differences between
placebo and riboflavin as a prophylactic agent in
tension-type headache with regard to the secondary out-
come variables (mean intensity of headache attacks and
mean duration of headache attacks) was not possible.
A prophylactic effect of riboflavin on tension-type
headache has not yet been described either in adults
or in children (11–14,19,24). In these latter studies,
headache frequency or migraine frequency was used
as outcome variable and there was no separate analysis
regarding tension-type headache or (other)
non-migraine headache attacks.
Based on our study, one might argue that a medium
dose of riboflavin has a prophylactic effect on
tension-type headache in children. From that perspec-
tive, one has to bear in mind that the tension-type head-
aches in our study were an accompanying phenomenon
in children with migraine as their main primary head-
ache. Also, at baseline, the total number of children
with both migraine and tension-type headache in both
groups (riboflavin-placebo and placebo-riboflavin) was
low, especially in the placebo-riboflavin group (50%
and 18%, respectively).
In addition, one can speculate about the nature of
accompanying tension-type headaches in children with
migraine, especially since the Spectrum Study of Lipton
et al. (26) provides evidence that all headache attacks in
adults with migraine more or less represent a spectrum
of migraine headaches. If one assumes that this is also
the case in children, based on the present study one
might conclude that riboflavin at a low dose reduces
mild, but not severe, headaches in migrainous children.
Therefore, caution is required when drawing conclu-
sions about the prophylactic effect of riboflavin on
tension-type headache in children. However, this is the
first study giving indications that riboflavin can diminish
tension-type headache in children with migraine com-
pared with a placebo intervention. To investigate if ribo-
flavin indeed has a primary effect on tension-type
headache in children or adults, more placebo-controlled,
randomised, double-blind trials need to be performed in
children or adults with primary tension-type headache
with and without migraine.
Conclusions
The present study shows that riboflavin in a dosage of
50mg/day has no effect on migraine prophylaxis in
young children with migraine compared with placebo.
Currently, there is inconclusive evidence that riboflavin
has a prophylactic effect on migraine attacks in chil-
dren. However, in this study, we give evidence that
riboflavin may have a prophylactic effect on interval
headaches that may correspond to mild migraine
attacks or tension-type headaches in children with
migraine. More studies are needed to investigate
whether the same prophylactic effect of riboflavin on
migraine as seen in adults can be achieved in children.
More studies are also needed to investigate the effect of
riboflavin on tension-type headache, both in children
and adults with and without migraine.
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